US Stem Cell Inc (USRM)

[docprep]

RTT doesn't truly maximize stem cell therapy potential as RMAT would.

RTT is only suitable for a narrow portion of people, in a narrow portion of fields where life ending disease treatment is there.

RMAT widens the field substantially allowing not yet FDA approved (fully) treatments that have been shown to be safe, even if not yet proven efficacy, to be actually tested in the real world

This will be the fastest way to accelerate the market, and of course most important to us, skyrocketing the revenue and profits.



I don't believe USRM has really any choice but to pursue RMAT if the guidelines apply to their products and treatments, as it is the quickest way to get to market. I have read the guidelines, and believe it is perfect for USRM and USCC.

I don't believe RTT laws allow for enough instances in time for these treatments to catch on as we would like/want them to.

I also think while RMAT may be expensive, it would certainly be less expensive than fighting the powers that be in trying to prove that its not a "drug".

The pathway guidelines are set, and it would be ignorant by management not to take advantage of this opportunity. Other stem cell companies will, and will leave USRM in the dust if we dont.

I trust KC and MT to do the right thing..